Fortigel testosterone: Phase III data

In the open-label, U.S. Phase III Fortify trial in 149 patients, Fortigel met the primary endpoint of >=75% of patients achieving a plasma testosterone reference range of 300-1,140 ng/dL at day 90. Th...